UPDATES
$Immutep (IMMP.US)$ Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting; Efti In Combination With Pembrolizumab And Radiotherapy Demonstrates Significant Efficacy In The Neoadjuvant Setting In Patients With Soft Tissue Sarcoma
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
